Today's journal articles

The effects of CD44 down-regulation on stem cell properties of head and neck cancer cell lines.

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites

Previous Journal Entries

Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2 Inflammation.

Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study.

Atypical chemokine receptors predict lymph node metastasis and prognosis in patients with cervical squamous cell cancer.

Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.

Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.

A Novel Monoclonal Antibody to Secreted Frizzled-Related Protein 2 Inhibits Tumor Growth.

Elevated level of peripheral CD8(+)CD28 (-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy.

Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.

A Phase I Study of Folate Immune Therapy (EC90 Vaccine Administered With GPI-0100 Adjuvant Followed by EC17) in Patients With Renal Cell Carcinoma.

Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model.

Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.

Effects of cyclophosphamide and IL-2 on regulatory CD4(+) T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.

Anticancer activities of anti-membrane antibodies against colon carcinoma cells undergoing chemotherapy.

Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells.

Prognostic Significance of Pretreatment F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using (131)I-Rituximab.

Potential implication of IL-24 in lymphangiogenesis of human breast cancer.

miR145 targets the SOX9/ADAM17 axis to inhibit tumor initiating cells and IL-6-mediated paracrine effects in head and neck cancer.

Oral Lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial.

Today's News Items

MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer

Training Courses & Meetings

No events listed

Previous News Items

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Supplemental BLA Accepted for Filing by the FDA

Roche\'s obinutuzumab (GA101) significantly reduced the risk of disease progression or death in people with one of the most common forms of blood cancer

New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

---

For faster discovery, automatically organize PubMed results into categories